Goldman Sachs initiates coverage on Infinity Pharmaceutical (NASDAQ: INFI) with a Neutral rating and $42 price target.

This article: 91 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE